ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 103 citations in OpenAlex.
- A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Trial
- Tepotinib in Non-Small-Cell Lung Cancer withThe New England journal of medicine · 2020Trial
- Research progress on resistance and mechanisms of c-Met inhibitors in treatingJournal of thoracic disease · 2026Review
- Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2026Review
- Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping.Discover oncology · 2026Article
- Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer.Respiratory research · 2026Article
- MYC contributes to targeted therapy resistance in lung cancers driven by MET exon 14-skipping alteration.NPJ precision oncology · 2026Article
- Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Biochemical Society transactions · 2025Review
- Progression of drug resistance or multiple primary lung cancer: a case report and literature review of a patient with mesenchymal-epithelial transition factor exon 14 skipping alterations lung adenocarcinoma.Anti-cancer drugs · 2025Review
- Evolving roles of MET as a therapeutic target in NSCLC and beyond.Nature reviews. Clinical oncology · 2025Review
- Targeting MET and KRAS G12C co-occurring mutation in metastatic adenoid cystic carcinoma of the trachea: a case report.Journal of medical case reports · 2025Article
- MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.Molecular oncology · 2025Article
- The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer.Cell reports. Medicine · 2025Review
- Article
- Review
- Clinicopathological features and genetic mutation spectrum of primary anastomosing hemangioma arising from the kidney.Frontiers in immunology · 2025Article
- Case Report: HGF and NF1 mutations as putative bypass mechanisms of MET inhibitor resistance in hepatocellular carcinoma: a case study.Frontiers in pharmacology · 2025Article
- Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.bioRxiv : the preprint server for biology · 2024Article
- Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.Clinical lung cancer · 2024Article
- Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth.Pharmaceuticals (Basel, Switzerland) · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 9 institutions in 2 countries.
Julia K RotowDepartment of Medicine, University of California, San Francisco, California.
Philippe GuiDepartment of Medicine, University of California, San Francisco, California.
Wei WuDepartment of Medicine, University of California, San Francisco, California.
Victoria M RaymondGuardant Health, Inc., Redwood City, California.ORCID 0000-0001-5223-0981
Richard B LanmanGuardant Health, Inc., Redwood City, California.ORCID 0000-0001-8122-4329
Frederic J KayeDepartment of Medicine, University of Florida, Gainesville, Florida.
Nir PeledSoroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel.
Ferran Fece de la CruzMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-2694-4838
Brandon NadresMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-4690-5978
Ryan B CorcoranMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Iwei YehHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.ORCID 0000-0002-3941-3561
Boris C BastianHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Petr StarostikDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida.
Kimberly NewsomDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida.
Victor R OlivasDepartment of Medicine, University of California, San Francisco, California.
Alexander M WolffDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California.
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California.ORCID 0000-0002-5080-2859
Eric A CollissonDepartment of Medicine, University of California, San Francisco, California.
Caroline E McCoachDepartment of Medicine, University of California, San Francisco, California.
D Ross CamidgeUniversity of Colorado, Aurora, Colorado.
Jose PachecoUniversity of Colorado, Aurora, Colorado.
Lyudmila BazhenovaUniversity of California, San Diego, California.
Tianhong LiDepartment of Internal Medicine, University of California, Davis, California.ORCID 0000-0001-7422-3520
Trever G Bivona *Department of Medicine, University of California, San Francisco, California. Collin.blakely@ucsf.edu trever.bivona@ucsf.edu.
Collin M Blakely *Department of Medicine, University of California, San Francisco, California. Collin.blakely@ucsf.edu trever.bivona@ucsf.edu.
University of California, San Francisco · USMassachusetts General Hospital · USUniversity of Florida · USCancer Research Institute · USGuardant (United States) · USUniversity of Colorado Anschutz Medical Campus · USBen-Gurion University of the Negev · ILUniversity of California, Davis · USUniversity of California System · US
Funding
UCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona, Jack Roth · 2017 to 2026
$12.9MProject 2U54CA224068 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE, FLAHERTY, KEITH T · 2017 to 2021
$6.3MThe Cancer Target Discovery and Development Network at UCSFU01CA217882 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANDYOPADHYAY, SOURAV, BIVONA, TREVER G · 2017 to 2021
$5.2MOrganoid-based Discovery of Oncogenic Drivers and Treatment Resistance MechanismsU01CA217851 · NCI · STANFORD UNIVERSITY · PI CURTIS, CHRISTINA N, JI, HANLEE P · 2017 to 2021
$4.7MVisualization hub for genomics data exploration and translational discoveryU24CA210974 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI COLLISSON, ERIC, HAUSSLER, DAVID H · 2016 to 2020
$4.2MCharacterization of YAP as a rational companion target in lung cancerR01CA204302 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona · 2017 to 2026
$3.7MRational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer TreatmentR01CA169338 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2013 to 2023
$3.4MGenomics and Functional Characterization of NF1-mutated Lung CancerR01CA227807 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC · 2018 to 2022
$2.8MThe structural and functional basis of MET exon 14 activation and acquired drug resistanceR01CA230263 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC, JURA, NATALIA · 2019 to 2023
$2.0MOptimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutationsR01CA239604 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLISSON, ERIC · 2019 to 2023
$2.0MOptimizing biologically-based rational polytherapy in ALK+ lung cancerR01CA211052 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2017 to 2021
$1.8MDoris Duke Charitable Foundation 2018110NCI NIH HHS R01 CA169338NCI NIH HHS R01 CA204302NCI NIH HHS R01 CA211052NCI NIH HHS R01 CA227807NCI NIH HHS R01 CA230263NCI NIH HHS R01 CA239604NCI NIH HHS U01 CA217851NCI NIH HHS U01 CA217882NCI NIH HHS U24 CA210974NCI NIH HHS U54 CA224068NCI NIH HHS U54 CA224081
Abstract
purposeAlthough patients with advanced-stage non-small cell lung cancers (NSCLC) harboring EXPERIMENTAL
designTargeted sequencing analysis was performed on cell-free circulating tumor DNA obtained from 289 patients with advanced-stage
resultsProminent co-occurring RAS-MAPK pathway gene alterations (e.g., in
conclusionsOur study provides a genomic landscape of co-occurring alterations in advanced-stage
Indexed as
ExonsAgedAnimalsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell-Free Nucleic AcidsCrizotinibFemaleHumansLung NeoplasmsMaleMAP Kinase Signaling SystemMiceMice, Inbred BALB CMiddle AgedMolecular Targeted TherapyBiomarkers, TumorCell-Free Nucleic AcidsCrizotinibMET protein, humanOncogene Protein p21(ras)Protein Kinase InhibitorsProto-Oncogene Proteins c-met
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.